Global Blood Therapeutics (GBT) announced that it had received FDA approval for its drug Oxbryta (voxelotor) in treating adults and children ages 12 years and older with sickle cell disease ((SCD)). This is a good approval for the biotech, and it will be able to target a large market with its newly approved drug. There might be some competition from a newly approved drug from another pharmaceutical company in a small sense, which I will describe below. However, this is good news for the company which is looking at expanding the market potential with another